NCT01289210

VTX-2337 in Combination With Radiotherapy in Patients Low-Grade B-cell Lymphomas

A Phase I/II Study of Intratumoral Injection of the Small Molecule TLR8 Agonist VTX-2337 in Combination With Local Radiation in Low-Grade B-cell Lymphomas

• Status: Terminated
• Phase: Phase 1 / Phase 2
• Study type: Interventional
• Enrollment: 2 (actual)
• Sponsor: Celgene · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study is to determine the safety and effectiveness of VTX-2337 (an investigational drug that stimulates the immune system) in combination with radiation therapy in treating patients with low-grade B-cell lymphoma. Patients will receive 2 low doses of radiotherapy, and 9 intratumoral injections of VTX-2337 over the course of 3 months.

Conditions

• Low Grade B Cell Lymphoma

Interventions

Type	Name	Description
DRUG	VTX-2337 plus radiotherapy	Radiation on Day 1. On Day 2, VTX-2337 3.0mg/m2 is administered intratumorally, followed by radiation. VTX-2337 3.0mg/m2 is then given weekly for 3 weeks in a 4 week cycle over 3 cycles.

Timeline

• Start date: 2011-07-01
• Primary completion: 2011-11-01
• Completion: 2012-10-01
• First posted: 2011-02-03
• Last updated: 2019-09-25
• Results posted: 2014-10-06

Locations

1 site across 1 country: United States